Chuck Grassley actually said...

Our investigation found that the PBM scheme encourages drug makers to spike the drug's list price in order to offer a greater rebate.

It is shocking that a commissioner would choose to resign rather than watch an agency's bipartisan tradition crumble in front of her eyes.

PBMs are blocking a cheaper product.

The Cantwell-Grassley PBM transparency bill directs the FTC to end well-known and documented PBM practices that drive up consumer price.